Anthony J J HickeyDr. Hickey is Distinguished RTI Fellow, at the Research Triangle Institute and Director of the UNC Catalyst for Rare Diseases of the Eshelman School of Pharmacy He obtained Ph.D. and D.Sc. degrees in pharmaceutical sciences from Aston University, Biringham, UK. He is a Fellow of the Royal Society of Biology, the American Association of Pharmaceutical Scientists, the American Association for the Advancement of Science and the Royal Society of Medicine. He received the Research Achievement Award of the Particulate Presentations and Design Division of the Powder Technology Society of Japan, the Distinguished Scientist Award of the American Association of Indian Pharmaceutical Scientists; the David W Grant Award in Physical Pharmacy of the American Association of Pharmaceutical Scientists; Thomas T Mercer Joint Prize for Excellence in Inhaled Medicines and Pharmaceutical Aerosols of the American Association for Aerosol Research and the International Society for Aerosols in Medicine and the Ralph Shangraw Memorial Award for Excipient and Excipient Technology of the International Pharmaceutical Excipient Consortium Foundation. He is founder (and formerly President and CEO) of Cirrus Pharmaceuticals, Inc., acquired by Kemwell Pharma; founder (formerly CSO, 2002-2007) of Oriel Therapeutics, Inc, acquired by Sandoz and founder and CEO of Astartein, Inc.; member of the Pharmaceutical Dosage Forms Expert Committee of the United States Pharmacopeia and formerly Chair of the Aerosols Expert Committee of the USP. Dr. Hickey conducts multidisciplinary research programs in the field of pulmonary drug and vaccine delivery for the treatment and prevention of a variety of diseases and oversees research in target and candidate therapeutic agent identification for rare and neglected diseases. Read More Read Less